A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

Status:
Completed

Trial end date:
2003-11-01

Target enrollment:

Participant gender:

This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents

Phase 1/Phase 2

Novartis

Maleic acid